药物治疗与膝骨关节炎长期疼痛控制的关联:系统综述与Meta分析
贝叶斯网络Meta分析显示,与安慰剂相比,塞来昔布和硫酸氨基葡萄糖与疼痛减轻相关,但所有效应估计均存在较大不确定性;硫酸氨基葡萄糖、硫酸软骨素和雷奈酸锶与关节间隙狭窄改善相关。结论认为需更大规模RCT以明确药物疗效。
要点
- 硫酸氨基葡萄糖与膝骨关节炎疼痛减轻及关节间隙狭窄改善相关。
- 塞来昔布与疼痛减轻相关,但证据不确定性大。
- 硫酸软骨素和雷奈酸锶与关节间隙狭窄改善相关。
核心结论
- 在随访至少12个月的膝骨关节炎患者中,所有与安慰剂比较的疼痛变化效应量估计均存在不确定性。
- 需要更大规模的随机临床试验来解决膝骨关节炎药物疗效的不确定性。
研究设计与样本
- 检索MEDLINE、Scopus、EMBASE、Web of Science和Cochrane Central Register of Controlled Trials至2018年6月30日,纳入治疗和随访持续1年及以上的RCT。
- 患者平均年龄范围大多为55-70岁,女性平均比例约70%,高于男性。
- 试验持续时间范围为1至4年。
- 主要结局为膝关节疼痛较基线的平均变化,次要结局为身体功能和关节结构(影像学关节间隙狭窄)。
主要发现
- 与安慰剂相比,塞来昔布与疼痛减轻相关(SMD,-0.18 [95% CrI,-0.35至-0.01])。
- 与安慰剂相比,硫酸氨基葡萄糖与疼痛减轻相关(SMD,-0.29 [95% CrI,-0.49至-0.09])。
- 当使用0至100量表的平均差分析并排除高偏倚风险试验时,仅硫酸氨基葡萄糖与疼痛改善的关联仍显著。
- 硫酸氨基葡萄糖与关节间隙狭窄改善相关(SMD,-0.42 [95% CrI,-0.65至-0.19])。
- 硫酸软骨素与关节间隙狭窄改善相关(SMD,-0.20 [95% CrI,-0.31至-0.07]),雷奈酸锶亦相关(SMD,-0.20 [95% CrI,-0.36至-0.05])。
临床怎么用
- 对于膝骨关节炎的长期管理,硫酸氨基葡萄糖可考虑用于疼痛控制和关节结构保护,但需告知患者证据不确定性。
- 塞来昔布与长期疼痛减轻相关,但效应估计不确定性大,临床决策需结合患者具体情况。
- 硫酸软骨素和雷奈酸锶与关节间隙狭窄改善相关,可作为结构保护的选择之一。
局限性
- 所有与安慰剂比较的效应量估计均存在较大不确定性。
- 需要更大规模的随机临床试验来确认药物疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Even though osteoarthritis is a chronic and progressive disease, pharmacological agents are mainly studied over short-term periods, resulting in unclear recommendations for long-term disease management. OBJECTIVE: To search, review, and analyze long-term (≥12 months) outcomes (symptoms, joint structure) from randomized clinical trials (RCTs) of medications for knee osteoarthritis. DATA SOURCES AND STUDY SELECTION: The databases of MEDLINE, Scopus, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials were searched until June 30, 2018 (MEDLINE alerts through August 31, 2018) for RCTs of patients with knee osteoarthritis that had treatment and follow-up lasting 1 year or longer. DATA EXTRACTION AND SYNTHESIS: Data at baseline and at the longest available treatment and follow-up of 12 months' duration or longer (or the change from baseline) were extracted. A Bayesian random-effects network meta-analysis was performed. MAIN OUTCOMES AND MEASURES: The primary outcome was the mean change from baseline in knee pain. Secondary outcomes were physical function and joint structure (the latter was measured radiologically as joint space narrowing). Standardized mean differences (SMDs) and mean differences with 95% credibility intervals (95% CrIs) were calculated. Findings were interpreted as associations when the 95% CrIs excluded the null value. RESULTS: Forty-seven RCTs (22 037 patients; mean age range, mostly 55-70 years; and a higher mean proportion of women than men, around 70%) included the following medication categories: analgesics; antioxidants; bone-acting agents such as bisphosphonates and strontium ranelate; nonsteroidal anti-inflammatory drugs; intra-articular injection medications such as hyaluronic acid and corticosteroids; symptomatic slow-acting drugs in osteoarthritis such as glucosamine and chondroitin sulfate; and putative disease-modifying agents such as cindunistat and sprifermin. Thirty-one interventions were studied for pain, 13 for physical function, and 16 for joint structure. Trial duration ranged from 1 to 4 years. Associations with decreases in pain were found for the nonsteroidal anti-inflammatory drug celecoxib (SMD, -0.18 [95% CrI, -0.35 to -0.01]) and the symptomatic slow-acting drug in osteoarthritis glucosamine sulfate (SMD, -0.29 [95% CrI, -0.49 to -0.09]), but there was large uncertainty for all estimates vs placebo. The association with pain improvement remained significant only for glucosamine sulfate when data were analyzed using the mean difference on a scale from 0 to 100 and when trials at high risk of bias were excluded. Associations with improvement in joint space narrowing were found for glucosamine sulfate (SMD, -0.42 [95% CrI, -0.65 to -0.19]), chondroitin sulfate (SMD, -0.20 [95% CrI, -0.31 to -0.07]), and strontium ranelate (SMD, -0.20 [95% CrI, -0.36 to -0.05]). CONCLUSIONS AND RELEVANCE: In this systematic review and network meta-analysis of studies of patients with knee osteoarthritis and at least 12 months of follow-up, there was uncertainty around the estimates of effect size for change in pain for all comparisons with placebo. Larger RCTs are needed to resolve the uncertainty around efficacy of medications for knee osteoarthritis.
引用
- Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 30575881. doi:10.1001/jama.2018.19319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。